The European Commission is launching a new strategy to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry, addressing mainly:
- the life cycle of medicines from R&D to authorisation and patient access
- how to put scientific and technological advances into practice
- how to fill market gaps (e.g. new antimicrobials)
- lessons learnt from COVID-19 on how to better prepare for future pandemics
Consorzio per Valutazioni Biologiche e Farmacologiche as coordinator of the European Paediatric Translational Research Infrastructure (EPTRI) provided its comments underlining the necessity to stress new adequate health policies and actions promoting the development and the access to safe and efficacious medicines specific for children. In fact, specific efforts should be made to guarantee innovative and high-quality health care, available for all citizens with particular attention for the groups, e.g. paediatric and rare diseases populations, often excluded by last advancements in the health field.
It is possible to read the complete document at this link.
It is possible to participate to the Public Consultation until 15 September 2020 by filling in the online questionnaire available at this link.